Repeated DOI and SR 46349B treatments do not affect elevated plus-maze anxiety despite opposite effects on cortical 5-HT(2A) receptors

Francis Chaouloff, Alexander Kulikov, Pierre Mormède
European Journal of Pharmacology. 1997-09-01; 334(1): 25-29
DOI: 10.1016/S0014-2999(97)01197-7

Read on PubMed

Chaouloff F(1), Kulikov A, Mormède P.

Author information:
(1)Génétique du Stress, INSERM CJF 94-05 INRA, Institut Francois Magendie,
Bordeaux, France.

We report the consequences of a 4-day treatment (b.i.d) with the 5-HT2A,2B,2C
receptor agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI, 1.5 mg/kg)
or the selective 5-HT2A receptor antagonist
nyl)propen-1-yl]phenol hemifumarate (SR 46349B, 7.5 mg/kg) on (i)
anxiety-related behaviour in an elevated plus-maze, and (ii) specific
[3H]ketanserin binding at central 5-HT2A receptors, in Roman rats. Neither DOI
nor SR 46349B pretreatment affected the behaviour in the open arms of the
elevated plus-maze; however, DOI pretreatment promoted discrete changes in the
closed arm entries. The Bmax value of [3H]ketanserin binding at cortical 5-HT2A
receptors was decreased by repeated DOI pretreatment. Conversely, Bmax, but also
KD, values were increased by SR 46349B pretreatment. Thus, changes at central
5-HT2A receptors may occur without there being changes in anxiety-related
behaviour in the elevated plus-maze.


Know more about